Trans & Non-binary Reference Intervals While on Hormone Therapy Study

Hormone Replacement Therapy Clinical Trial

— TransRIHTS  

Official title:

Reference Intervals for 27 Routine Chemistry and Immunoassay Tests in Transgender Adults on Stable Hormone Therapy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04478760
• Other study ID #: TransRIHTS Protocol
• Status: Recruiting
• Start date: April 13, 2021
• Est. completion date: April 2024

Study information

• Verified date: March 2024
• Source: King's College Hospital NHS Trust
• Contact: Devon Buchanan, MSc
• Email: devon.buchanan[@]nhs.net
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study will find out what the reference intervals are for common blood tests in transgender people taking hormone therapy.

Reference intervals help doctors interpret blood test results. They are expressed as two numbers, and most normal results fall between them. If a results fall outside of them, it may be because of a disease. Some blood tests are also affected by normal difference between people, such as age, sex or ethnicity. For these tests, different reference intervals are given for each group of people. Having accurate reference intervals benefits patients because it allows doctors to identify disease faster.

Transgender people have a gender identity which does not match their sex characteristics at birth. Gender identity is the feeling of being a gender, and sex is the biological aspects of growing up male or female. Transgender people may use hormone therapy to help change their appearance to fit their gender identity. This involves taking either oestrogen or testosterone.

For blood tests which are affected by sex, it is not clear what reference intervals should be used for transgender people who are on hormone therapy. This is because they have a mixture of male and female sex characteristics. Answering this question will allow doctors to identify disease in them faster.

The study will take place at cliniQ, at King's College Hospital, which provides health services to transgender people. It will recruit healthy transgender people who attend the clinic for blood tests to monitor their hormone therapy. Participants will fill out a questionnaire, give a urine sample, then have their appointment as normal. Extra tests will also be performed on their blood sample. The aim is to recruit 240 participants. Participant's tests results will then be used to calculate reference intervals.

The study is funded by Viapath Group LLP.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 240
• Est. completion date: April 2024
• Est. primary completion date: April 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Transgender or nonbinary people.

• Aged 18 or older.

• Taking testosterone or oestrogen therapy.

• For 12 months or more.

• Having routine hormone therapy monitoring at the clinic.

Exclusion Criteria:

• Unable to give informed consent (including participants who cannot communicate in English).

• History of chronic liver disease, chronic kidney disease, diabetes, or severe cardiovascular disease (including myocardial infection, deep vein thrombosis, stroke and pulmonary embolism).

• Blood test results that indicate severe disease.

• Pregnant or within one year after childbirth.

• Other conditions which could put participants at risk by participating, or which could influence the results of the study.

Related Conditions & MeSH terms

• Hormone Replacement Therapy
• Reference Values
• Transgender Persons

Locations

Country	Name	City	State
United Kingdom	Caldecot Centre, King's College Hospital, 15-22 Caldecot Road	London

Sponsors (1)

Lead Sponsor	Collaborator
King's College Hospital NHS Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Reference interval for transgender patients on hormone therapy	Establish reference intervals for routine chemistry and immunoassay test for transgender people on hormone therapy. Establish separate reference intervals for people on masculinising and feminising therapy if they differ substantially.	1 day
Secondary	Compare the reference intervals in patients taking different hormone therapy formulations.	Compare different hormone therapy formulations to establish whether there are clinically significant difference in their effects on reference intervals.	1 day
Secondary	Compare transgender reference intervals to the existing ones	Compare the reference values for transgender people on hormone therapy with the existing cisgender reference intervals to establish whether they are similar enough for the cisgender reference intervals to be used instead.	1 day